Unique contribution of one patient advocacy organization in advancing cerebral cavernous malformation awareness and research

Abstract

Advocacy organizations have long played a role in advancing care and research for patients affected by rare disease. Angioma Alliance has served traditional functions of organizing scientific meetings and creating shared resources like a tissue bank and a patient registry. Uniquely, the organization has employed creative patient engagement methods like subsidized genetic testing as well as targeting special populations to expand research participation and understanding of the illness. Special populations include those with CCM3 mutations, the CCM1 Common Hispanic Mutation, and Black patients.

Keywords

Cavernous / angioma / malformation / cavernoma / advocacy / cerebrovascular disorders / patient cohorts / patient community / Hispanic / founder mutation

References

[1] Gault J,Hu LJ.Spectrum of genotype and clinical manifestations in cerebral cavernous malformations.Neurosurgery2006;59:1278-84; discussion 1284-5

[2] Shenkar R,Rebeiz T.Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations.Genet Med2015;17:188-96 PMCID:PMC4329119

[3] Tang AT,Hong CC.Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation.Sci Transl Med2019;11:eaaw3521 PMCID:PMC6937779

[4] Gunel M,Finberg K.A founder mutation as a cause of cerebral cavernous malformation in Hispanic Americans.N Engl J Med1996;334:946-51

[5] Liquori CL,Squitieri F.Deletions in CCM2 are a common cause of cerebral cavernous malformations.Am J Hum Genet2007;80:69-75 PMCID:PMC1785317

[6] U.S. Food & Drug Administration. Enhancing the diversity of clinical trial populations - eligibility criteria, enrollment practices, and trial designs guidance for industry, November 2020. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial [Last accessed on 2 Nov 2021]